iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14, Zacks reports.
iTeos Therapeutics Stock Performance
NASDAQ ITOS traded up $0.27 during trading on Friday, hitting $7.77. The stock had a trading volume of 366,462 shares, compared to its average volume of 486,487. iTeos Therapeutics has a 12 month low of $4.80 and a 12 month high of $18.75. The company's 50-day moving average price is $6.59 and its two-hundred day moving average price is $7.54. The company has a market capitalization of $296.77 million, a PE ratio of -2.47 and a beta of 1.43.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company dropped their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating on the stock in a research note on Tuesday. Wedbush reiterated an "outperform" rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright restated a "buy" rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th.
Get Our Latest Stock Analysis on ITOS
iTeos Therapeutics Company Profile
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Read More
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
